全文获取类型
| 收费全文 | 1919976篇 |
| 免费 | 127130篇 |
| 国内免费 | 5279篇 |
专业分类
| 耳鼻咽喉 | 24749篇 |
| 儿科学 | 62470篇 |
| 妇产科学 | 50666篇 |
| 基础医学 | 285037篇 |
| 口腔科学 | 53086篇 |
| 临床医学 | 180967篇 |
| 内科学 | 365686篇 |
| 皮肤病学 | 39730篇 |
| 神经病学 | 151683篇 |
| 特种医学 | 69371篇 |
| 外国民族医学 | 430篇 |
| 外科学 | 270467篇 |
| 综合类 | 41663篇 |
| 现状与发展 | 3篇 |
| 一般理论 | 603篇 |
| 预防医学 | 156022篇 |
| 眼科学 | 42775篇 |
| 药学 | 142421篇 |
| 44篇 | |
| 中国医学 | 5186篇 |
| 肿瘤学 | 109326篇 |
出版年
| 2021年 | 15433篇 |
| 2019年 | 16413篇 |
| 2018年 | 22324篇 |
| 2017年 | 17013篇 |
| 2016年 | 18570篇 |
| 2015年 | 21051篇 |
| 2014年 | 28845篇 |
| 2013年 | 44234篇 |
| 2012年 | 60235篇 |
| 2011年 | 63754篇 |
| 2010年 | 37200篇 |
| 2009年 | 34471篇 |
| 2008年 | 58615篇 |
| 2007年 | 62153篇 |
| 2006年 | 62749篇 |
| 2005年 | 60020篇 |
| 2004年 | 57601篇 |
| 2003年 | 54761篇 |
| 2002年 | 53216篇 |
| 2001年 | 89236篇 |
| 2000年 | 91495篇 |
| 1999年 | 76378篇 |
| 1998年 | 21057篇 |
| 1997年 | 18643篇 |
| 1996年 | 18731篇 |
| 1995年 | 17787篇 |
| 1994年 | 16534篇 |
| 1993年 | 15413篇 |
| 1992年 | 60104篇 |
| 1991年 | 58959篇 |
| 1990年 | 57211篇 |
| 1989年 | 55117篇 |
| 1988年 | 50739篇 |
| 1987年 | 49353篇 |
| 1986年 | 47019篇 |
| 1985年 | 44630篇 |
| 1984年 | 33301篇 |
| 1983年 | 28375篇 |
| 1982年 | 16572篇 |
| 1979年 | 30320篇 |
| 1978年 | 21434篇 |
| 1977年 | 17776篇 |
| 1976年 | 17284篇 |
| 1975年 | 18131篇 |
| 1974年 | 21935篇 |
| 1973年 | 21290篇 |
| 1972年 | 19789篇 |
| 1971年 | 18417篇 |
| 1970年 | 17304篇 |
| 1969年 | 15838篇 |
排序方式： 共有10000条查询结果，搜索用时 15 毫秒
1.
2.
3.
4.
Stelter K. Theodoraki M. N. Becker S. Tsekmistrenko V. Olzowy B. Ledderose G. 《European archives of oto-rhino-laryngology》2015,272(3):639-639
European Archives of Oto-Rhino-Laryngology - 相似文献
5.
6.
7.
8.
Jae Eun Choi Tyler Werbel Zhenping Wang Chia Chi Wu Tony L. Yaksh Anna Di Nardo 《Journal of dermatological science》2019,93(1):58-64
Background
Rosacea is a chronic inflammatory skin condition whose etiology has been linked to mast cells and the antimicrobial peptide cathelicidin LL-37. Individuals with refractory disease have demonstrated clinical benefit with periodic injections of onabotulinum toxin, but the mechanism of action is unknown.Objectives
To investigate the molecular mechanism by which botulinum toxin improves rosacea lesions.Methods
Primary human and murine mast cells were pretreated with onabotulinum toxin A or B or control. Mast cell degranulation was evaluated by β-hexosaminidase activity. Expression of botulinum toxin receptor Sv2 was measured by qPCR. The presence of SNAP-25 and VAMP2 was established by immunofluorescence. In vivo rosacea model was established by intradermally injecting LL-37 with or without onabotulinum toxin A pretreatment. Mast cell degranulation was assessed in vivo by histologic counts. Rosacea biomarkers were analyzed by qPCR of mouse skin sections.Results
Onabotulinum toxin A and B inhibited compound 48/80-induced degranulation of both human and murine mast cells. Expression of Sv2 was established in mouse mast cells. Onabotulinum toxin A and B increased cleaved SNAP-25 and decreased VAMP2 staining in mast cells respectively. In mice, injection of onabotulinum toxin A significantly reduced LL-37-induced skin erythema, mast cell degranulation, and mRNA expression of rosacea biomarkers.Conclusions
These findings suggest that onabotulinum toxin reduces rosacea-associated skin inflammation by directly inhibiting mast cell degranulation. Periodic applications of onabotulinum toxin may be an effective therapy for refractory rosacea and deserves further study. 相似文献9.
M. Iachina P.M. Ljungdalh R.G. Sørensen L. Kaerlev J. Blaakær O. Trosko N. Qvist B.M. Nørgård 《Clinical oncology (Royal College of Radiologists (Great Britain))》2019,31(2):115-123
Aims
To examine the influence of pre-existing psychiatric disorder on the choice of treatment in patients with gynaecological cancer.Materials and methods
The analyses were based on all patients who underwent surgical treatment for endometrial, ovarian or cervical cancer who were registered in the Danish Gynecological Cancer Database in the years 2007–2014 (3059 patients with ovarian cancer, 5100 patients with endometrial cancer and 1150 with cervical cancer). Logistic regression model and Cox regression model, adjusted for relevant confounders, were used to estimate the effect of pre-existing psychiatric disorder on the course of cancer treatment. Our outcomes were (i) presurgical oncological treatment, (ii) macroradical surgery for patients with ovarian cancer, (iii) radiation/chemotherapy within 30 days and 100 days after surgery and (iv) time from surgery to first oncological treatment.Results
In the group of patients with ovarian cancer, more patients with a psychiatric disorder received macroradical surgery versus patients without a psychiatric disorder, corresponding to an adjusted odds ratio of 1.24 (95% confidence interval 0.62–2.41) and the chance for having oncological treatment within 100 days was odds ratio = 1.26 (95% confidence interval 0.77–2.10). As for patients with endometrial cancer, all outcome estimates were close to unity. The adjusted odds ratio for oncological treatment within 30 days after surgery in patients with cervical cancer with a history of psychiatric disorder was 0.20 (95% confidence interval 0.03–1.54).Conclusions
We did not find any significant differences in the treatment of ovarian and endometrial cancer in patients with pre-existing psychiatric diagnoses. When it comes to oncological treatment, we suggest that increased attention should be paid to patients with cervical cancer having a pre-existing psychiatric diagnosis. 相似文献10.
Stress Testing Versus CT Angiography in Patients With Diabetes and Suspected Coronary Artery Disease
Abhinav Sharma Adrian Coles Nishant K. Sekaran Neha J. Pagidipati Michael T. Lu Daniel B. Mark Kerry L. Lee Hussein R. Al-Khalidi Udo Hoffmann Pamela S. Douglas 《Journal of the American College of Cardiology》2019,73(8):893-902